News

New Digital ID Verification Solution Available To Turkish Fintech Apps

The goal is to provide a simpler solution for identity verification and remote customer acquisition to modern fintech apps in Turkey.

Published

3 years ago

April 29, 2021

Joanna Melki

new digital id verification solution available to turkish fintech apps

If there’s anything positive about the coronavirus pandemic and the global wave of lockdowns that followed in response to it, it’s the rapid acceleration of digitalization across all industries. Responding to the fintech companies in Turkey, Insha Ventures and Identify Turkey have created a digital ID verification solution called KimlikBasit.

The goal of KimlikBasit is to provide a simpler solution for identity verification and remote customer acquisition to modern fintech apps, whose digital-only nature clashes with face-to-face verification of customer credentials.

“KimlikBasit is a fintech venture operating in the field of call center-supported remote customer acquisition, providing artificial intelligence-supported biometric data comparison and verification, with solutions designed for businesses, especially financial institutions, to prevent money laundering and identity fraud (AML/KYC),” explains Yakup Sezer, general manager of Insha Ventures.

Users who encounter KimlikBasit in the wild are required to go through only a few simple steps to complete the verification process. First, user information for remote customer acquisition is taken. The user is then redirected to the actual verification process, which consists of document scanning using a mobile device and a brief call with a call center employee. After successful verification, all user information is stored in a secure manner and can be accessed via an administration panel.

Also Read: UAE Is Ready To Test New Face ID Technology In Service Delivery

“We are excited to be a critical part of this digital transformation while witnessing the transformation of the sectors in Turkey through regulations,” said Ali Haydar Ünsal, general manager of Identify Turkey. “In this period when the customer experience has undergone a significant change, we make it easier for companies in critical sectors such as e-commerce, banking, automotive and capital markets to acquire new customers within 10 minutes.”

Fintech apps that would like to implement KimlikBasit can look forward to 24/7 customer support provided by expert teams in multiple languages and a wealth of training material to help with the implementation of this innovative digital ID verification solution.

News

Orchid Plans To Find Out What’s Wrong With You Before You’re Born

According to CEO Noor Siddiqui, the company isn’t on a mission to make designer babies, but aims to beat genetic odds and relieve suffering.

Published

4 hours ago

May 7, 2024

Nour Nasir

Orchid

Each day, around 400,000 babies are welcomed into the world. However, among those, a growing number will experience some kind of birth defect or inherited disease.

Noor Siddiqui, CEO of Orchid, hopes to “mitigate” unpleasant genetic surprises using genome sequencing technology to reveal a wealth of genetic information on which newborns will grow into healthy adults.

Until 2019, IVF specialists had access to under 1% of the human genome. The tests, called PGT-A and PGT-M, scanned a mere 1,000 data points in a genome comprising around 3 billion bases, offering a very limited dataset compared to the technology used by Orchid.

“Our chromosomes are like chapters in a book that make up the table of contents.” Explained Siddiqui. “[PGT-A and PGT-M tests] only examine the table of contents, whereas what Orchid is doing is like a spellcheck on the entire book.” Orchid’s genome sampling technology assesses “100 times the data, covering many more conditions.” In essence, an Orchid report covers three categories of common genetic issues: monogenic disorders, polygenic conditions, and de-novo mutations.

Also Read: Advancing MENA Health Through AI Vascular Age Analysis

Orchid’s technology raises many questions. Aside from the obvious ethical concerns, data privacy is the most obvious potential issue with the tests. Noor Siddiqui is keen to alleviate any concerns: “No data at Orchid is ever sold to any third parties. Parents are in complete control of their data. If they want to delete the data, we’re happy to delete it off of our servers. If they want to export the data, they can export the data. And if they want us to re-analyze the data, we can re-analyze the data”.

Compared to a lifetime of medical bills, gene therapy, and suffering, Orchid’s genome screening report has the potential to change the future lives of thousands of newborns worldwide.